TABLE 1.
H1/IC31 clinical trial overview and results
| Characteristica | Value for: |
|
|---|---|---|
| Placebo group (n = 4) | H1/IC31 vaccinated group (n = 19) | |
| Age (median [IQR]) (yr) | 38 (28−49) | 39 (34−45) |
| Gender (F/M) | 3/1 | 9/10 |
| No. (%) with prior BCG vaccination (self-report) | 4 (100) | 19 (100) |
| No. (%) ART naive | 4 (100) | 19 (100) |
| CD4 count (median [IQR]) from baseline (cells/mm3) | 575.3 (425–617)b | 656.9 (532−745)b |
| Viral load (median [IQR]) from baseline (copies/ml) | 33,802 (514–49,875)b | 37,932 (8,754−50,950)b |
a
IQR, interquartile range; F, female; M, male.
b
No significant difference over the 182-day follow-up.